ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.46
-0.52%
US Tech 100
19,430.40
0.14%
S&P 500
5,487.03
0.25%
US Dollar vs CAD
1.37135
-0.03%
Bitcoin
64,890.16
-0.38%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) News

SNDX

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNDX
DateTimeSourceHeadlineSymbolCompany
06/17/20248:26AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/14/20246:00AMPR Newswire (US)Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 CongressNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/10/20246:30AMGlobeNewswire Inc.Pyxis Oncology Expands Board of Directors with Appointment of Michael A. MetzgerNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/06/20246:00AMPR Newswire (US)Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRCNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/05/20246:00AMPR Newswire (US)Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
06/03/20243:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/16/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/16/20243:03PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/15/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/15/20243:05PMPR Newswire (US)Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of DirectorsNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/09/20246:00AMPR Newswire (US)Syndax Announces Participation at the Bank of America Securities 2024 Health Care ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/08/20246:06AMPR Newswire (US)Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/08/20246:04AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/08/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/03/20243:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
05/01/20246:00AMPR Newswire (US)Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
04/10/20243:05PMPR Newswire (US)Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:SNDXSyndax Pharmaceuticals Inc
04/08/20246:00AMPR Newswire (US)Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionNASDAQ:SNDXSyndax Pharmaceuticals Inc
04/05/20243:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
03/28/20246:00AMPR Newswire (US)Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
03/26/20243:05PMPR Newswire (US)Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
03/18/20246:00AMPR Newswire (US)Syndax Announces Appointment of Steven Closter as Chief Commercial OfficerNASDAQ:SNDXSyndax Pharmaceuticals Inc
03/01/20243:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
02/27/20244:28PMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:SNDXSyndax Pharmaceuticals Inc
02/27/20244:21PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SNDXSyndax Pharmaceuticals Inc
02/27/20243:05PMPR Newswire (US)Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
02/27/20243:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
02/26/20246:00AMPR Newswire (US)Syndax Announces Participation at Two Upcoming Investor ConferencesNASDAQ:SNDXSyndax Pharmaceuticals Inc
02/20/20243:05PMPR Newswire (US)Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
02/14/202411:50AMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SNDXSyndax Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SNDX

Your Recent History

USOTC
MWWC
Marketing Worldwide (PK)
USOTC
SFRX
Seafarer Exploration (PK)
USOTC
TSOI
Therapeutic Solutions (PK)
USOTC
BLLB
Bell Buckle (PK)
NASDAQ
NB
NioCorp Developments
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
CYDY
CytoDyn (QB)
NASDAQ
NVDA
NVIDIA
NASDAQ
COOP
Mr Cooper
NASDAQ
AMRN
Amarin
USOTC
SAPX
Seven Arts Entertainment (PK)
NASDAQ
DJT
Trump Media and Technology
NASDAQ
AVXL
Anavex Life Sciences
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved